Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis

Overview of attention for article published in Drug, Healthcare and Patient Safety, February 2016

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 41 followers.

Risk assessment of golimumab in the treatment of UC https://t.co/Ett2vOhaWa

Risk assessment of golimumab in the treatment of UC https://t.co/R0Zqq3CqwL